Background: Invasive mucinous lung adenocarcinomas are rare and account for 2%-10% of all lung adenocarcinoma cases. It is believed that Napsin A exhibits a weaker expression in mucinous adenocarcinomas compared with TTF1, but such correlation is still poorly researched. Aim: The aim of the study was to determine the frequency of mucinous to nonmucinous adenocarcinomas and compare specifi city and sensitivity of monoclonal Napsin A with TTF1 in mucinous adenocarcinomas and defi ne the frequency of EGFR mutations. Materials and methods: Eighty-four resected lung carcinomas were prospectively evaluated. All biopsies were analysed with p63, TTF1, monoclonal Napsin A, CK7, CK20 and CDX2 and were studied with real-time PCR technology. Results: In resected material we detected 49/84 (58.3%) adenocarcinomas and selected 21 mucinous adenocarcinomas out of 46 non-mucinous adenocarcinomas (45.6%). The most common pattern of mucinous adenocarcinomas is papillary -24% and colloidal -24%, followed by acinar -19.2% and lepidic -19.2%. mNapsin A was positive in 18/21 (85.7%) mucinous adenocarcinomas v/s 17/21 TTF1 positive (80.9%). EGFR mutations were detected in 3/21 cases with mucinous adenocarcinomas (14.3%): mucinous papillary, mucinous acinar and "salivary gland-like". Conclusion: Our study demonstrates a high proportion of primary mucinous lung adenocarcinomas to primary non-mucinous adenocarcinomas. Sensitivity and specifi city of mNapsin A and TTF1 did not show signifi cant diff erence in pulmonary mucinous and non-mucinous adenocarcinomas, as mNapsin A gave greater sensitivity to mucinous adenocarcinomas. Our results indicate the same mutation frequency of EGFR in mucinous adenocarcinomas as mutation frequency detected in non-mucinous adenocarcinomas in the Bulgarian region.
A new classifi cation of adenocarcinoma (AC) of the lungs was published in 2001. One of the major changes is the reclassifi cation of the carcinoma formerly known as mucinous bronchioloalveolar carcinoma (BAC) to "invasive mucinous adenocarcinoma (IMA)". IMA was classifi ed in a new category due to its unique radiologic, morphologic and genetic characteristics. 1, 2 An important morphological feature of mucinous adenocarcinomas (MAC) of the lung is mucin in the alveolar spaces and in tumor cells. These tumors histologically may also indicate alveolar, acinar, papillary, micropapillary or solid differentiation as non-mucinous AC. They should be distinguished from metastatic mucinous carcinomas of the colon, breast, stomach and others. 2, 3 Immunohistochemical (IHH) expression of Napsin A in primary pulmonary mucinous carcinomas is not well studied. It turns out that contrary to perceptions, primary lung adenocarcinomas with extracellular and intracellular mucin production are not uncommon. It is believed that Napsin A (NapsA) exhibits a weaker expression in MAC compared with TTF1, but such correlations are still poorly researched. 4 It is also considered that the histological subtype of adenocarcinomas, which is not an association with EGFR mutations, is the type with mucinous differentiation. EGFR mutations were not found in invasive mucinous adenocarcinomas or mucinous bronchioloalveolar adenocarcinomas (lepidic adenocarcinomas. 4 Typically, these tumors are associated with mutations in KRAS. 5 There are reports of greater chemoresistance in tumors previously categorized as BAC. 6, 7 The aim of our study is to determined the frequency of mucinous to non-mucinous AC, to comparable specifi city and sensitivity of NapsA with TTF1 in MAC and determine the frequency of EGFR mutations.
MATERIALS AND METHODS

BIOPSY SELECTION
From January 2013 to February 2015, we selected patients with newly diagnosed primary lung cancer which were consecutively enrolled. Inclusion criteria for this study were: 1) patients undergone complete resection of the primary lesion; 2) patients with clinically confi rmed primary tumor in the lung; 3) samples had a minimum of 200 tumor cells per block and suffi cient corresponding normal tissue for mutational analysis.
Eighty four resected lung tumors were evaluated according to the new IASLC/ATS/ERS lung adenocarcinoma classifi cation for resected material. Invasive mucinous adenocarcinomas were defi ned as a tumor with lepidic, acinar, papillary or micropapillary pattern, salivary gland-like tumor or colloidal AC with abundant extracellular mucin. Colloid-predominant adenocarcinoma was defi ned as a tumor with mucin pools within airspaces, with destruction of alveolar walls. Extracellular mucin was considered to be positive when observed in ≥50% of the tumor. All samples were tested with monoclonal antibody Napsin A (m-NapsA antibody) and TTF1.
IMMUNOHISTOCHEMICAL ANALYSIS
The 4-μm unstained slides were used for detection of the following antigens: NCL-L-Napsin A (monoclonal mouse; IP64, Novocastra, 1:400); TTF-1 (monoclonal mouse; SPT24, Dako, 1:200), CK7 (monoclonal mouse; OV-TL 12/30, Dako Cytomation), CK20 (monoclonal mouse; Dako Cytomation), CDX2 (monoclonal mouse; BioGenex). For antigen retrieval, formalin-fi xed, paraffi n-embedded tissue sections were deparaffi nized, hydrated, and heated in a steamer at an appropriate pH. Subsequently, slides were washed in Tris-buffer. Endogenous peroxidase was blocked with 3% H 2 O 2 for 5 minutes. Primary antibody incubation was performed for 1 hour at room temperature. Secondary antibody incubation with Post Primary Block was done for 25 min., followed by DAB Chromogen 1.74% (3,3'-diaminobenzidine tetrahydrochloride, Novo Link Polymer Detection System) application for 5 minutes. Chromogenic signal and compartmentalization were assessed by bright-fi eld microscopy and graded.
EGFR MUTATION ANALYSIS
All the specimens were formalin-fi xed paraffi nembedded (FFPE) tissue blocks obtained during surgical excision of the tumors. It had used 10 sections (5 μm thick) of paraffi n block to isolate DNA. The FFPE tissue DNA extraction came from QIAamp DNA FFPE Tissue Kit of Qiagen (Hilden, Germany). Exons 18-21 of EGFR were analysed by using polymerase chain reaction (PCR) based on Scorpions Amplifi cation Refractory Mutation System (SARMS) technology. The specifically designed EGFR RGQ PCR Kit allows the detection of 29 known somatic mutations (including the inhibitory mutation T790M) in exons 18-21 of the EGFR genes.
STATISTICAL ANALYSIS
We adopted Pearson's χ 2 test or Fisher's exact test to assess the correlations between pathological variables of IHH stains (TTF1 and NapsA). The statistical analyses were performed using SPSS 17.0 for Windows.
RESULTS
HISTOLOGIC FEATURES
Of 84 resected lung cancers, we found 49/84 АСs (58.3%). Three tumors were negative to all pulmonary markers and expressed CDX2 and CK20 and were evaluated as metastases of mucinous colorectal carcinomas (CRC) and were excluded from evaluation. We expected 46 primary lung AC. Mucinous АСs were 21/46 (45.6%) and 25/46 (54.3%) were non-mucinous АСs. The most common pattern of mucinous carcinomas was papillary and colloidal, followed by acinar and lepidic. NapsA was positive in 18/21 (85.7%) МАС v/s 17/21 TTF1 positive (80.9%). CK7 was positive in 18/21 MAC (85.7%), (Fig. 1) . CDX2/CK20 was negative in all expected cases of primary mucinous lung carcinomas ( Table 1) . Most common pattern of non-mucinous carcinomas was solid -48.0%, followed by papillary and micropapillary AC -46.0%. 
EGFR MUTATIONS
EGFR mutations were detected in 3/21 cases with mucinous AC (14.3%): mucinous papillary, mucinous acinar and salivary gland-like AC (Fig. 2) . Among non-mucinous AC, mutation frequency is 4/25 (16%) in this selected group ( Table 2) . DISCUSSION Invasive MAC account for 2%-10% of lung adenocarcinoma cases in East Asia, Europe, and the United States. 8, 9 They are considered to be more malignant than other common subtypes of lung adenocarcinoma such as lepidic and acinar subtypes. 10 MAC in the lung is a rare, but distinctive variant of pulmonary adenocarcinoma. In one of the largest series described by Rossi G et al. (2004) 2 MAC accounted for 0.24% of all lung cancers and the prognosis was often favorable. However, some recent reports have described a rare and aggressive clinical feature. 11 According to the latest WHO classifi cation of lung and pleural tumors, a diagnosis of MAC should be limited to fi ndings of neoplastic cells fl oating in large pools of mucus and focally lining the alveolar spaces. 3 Morphological response of mucin-producing carcinomas of the lung is extremely wide and is represented by several histologic subtypes including mucinous bronchioloalveolar adenocarcinoma, colloidal adenocarcinoma, annular-cell adenocarcinoma and mucinous cistadenocartcinoma. 12 Their diagnosis and differentiation from other subtypes of lung carcinomas are easy to make because of the formation of glandular structures and the production of mucus. Diffi culties arise from possibilities of differentiated metastatic gastrointestinal and mucinous ovarian adenocarcinomas.
Mucinous adenocarcinomas of the lung show a strong tendency toward multicentre growth pattern, multilobular and bilateral pulmonary airy distribution. Therefore, mucinous components must be described. MAC, which account for 2%-10% of lung adenocarcinoma cases in East Asia, Europe, and the United States, were considered to be more malignant than other common subtypes of lung adenocarcinoma, such as lepidic and acinar subtypes. 8 It turns out that contrary to perceptions, primary lung adenocarcinomas with extracellular and intracellular mucin production are not uncommon. On 13 divided lung MAC into two subgroups: mucus-in-cell adenocarcinoma (MICA) and mucusout-of-cell adenocarcinoma (MOCA). They found that patients with MICA showed a potential trend of better prognosis than the mucus-negative patients, while MOCAs seemed to have the worst prognosis of all three subgroups. When the mucus is out of the cell, the tumor may have aggressive biological behavior. These results indicated that IMA subtype alone may not be an adequate predictor for worse prognosis. 13 In our study, the proportion of primary mucinous AC also was high 21/46 -45.6%. NapsA was negative in 4 MAC (19.2%). Currently, thyroid transcription factor 1 (TTF1), which is a nuclear expression protein in type II pneumocytes and Clara cells of the lung, is the most commonly used immunohistochemical marker for identifi cation of lung AC. It is believed, however, that TTF1 is less In some recent immunohistochemical studies, however, it has been reported that NapsA expression in squamous cell carcinoma of the lung can reach 26%, which raises doubts that this marker might not be specifi c to lung adenocarcinomas, as is commonly believed. In a study of Ordóñez NG et al. (2012) 16 and also in our materials, it was found that because of the strong reactivity of NapsA in hyperplastic type II pneumocytes and alveolar macrophages, both of which are included within the tumor, incorrect diagnosis of mixed histologic subtype may sometimes be made. We also decided that the presence of these interpolated cells is the most likely cause of discrepancies. mNapsA displays strong expression in tissue macrophages and hyperplastic pneumocytes type II, which is a disadvantage in small materials, and can cause potential errors. Pathologists should be aware of this potential pitfall in interpretation of immunostaining for NapsA, especially in small samples and endoscope biopsies, lung tissue microarrays or cor biopsies.
In our study, of greater signifi cance is the coincidence of negative results. Double negative of mNapsA/TTF1 were 6/46 MAC (13.2%). In this study, both markers did not show signifi cant difference between sensitivity and specifi city of mNapsA -37/46 (81.4%) v/s TTF1 positive -38/46 (83.6%); (CI: 0.98-1,33; χ 2 <0001) in both mucinous and non-mucinous AC. Three metastases from colon, mucinous AC, were double negative which allowed for additional typing with CK20 and CDX2 their differentiation from primary lung MAC. Double negative turned out to be an atypical carcinoid with mucinous acinar structures (Synaptophуsin+). A primary outbreak in the small intestine was found in abdominal ultrasound scan.
Zenali MJ et al. (2015) 17 indicated frequent CDX2 expression in colloid carcinomas. Immuspecifi c in distinguishing primary and metastatic adenocarcinomas of the lung, because in certain types of mucin-producing lung tumors, especially mucinous BAC, TTF1 expression often is absent. 14 In our study, TTF1 was negative in 5/21 mucinous AC (24.0%). This confi rms the high percentage of TTF1-negative mucinous adenocarcinomas in the lung. On RM, TTF1 in mucinous AC is a less sensitive marker of Napsin A in terms of false negative samples (80.9% v/s 85.7%, χ 2 = 0.102).
Rekhtman N (2015) 15 found that polyclonal NapsA had at least focal labeling in nearly all (24 of 25) tested tumors, regardless of the site of origin. In contrast, m-NapsA antibody was completely negative in all extrapulmonary carcinomas. We do not fi nd signifi cant differences in sensitivity of the m-NapsA antibody and TTF1 to pulmonary MAC; 4 v/s 5 negative biopsies. In 17/21 MAC both markers were positive (81.6%), as a diffuse strong expression (N3) was observed in 20/21 tumors tested with TTF1 (96.0%), v/s 11/21 with intense cytoplasmic expression of NapsA (52.8%). This indicates a weaker intensity on expression of NapsA in mucinous AC, but not at a lower specifi city compared to TTF1. Monoclonal antibody NapsA was completely negative in all metastatic mucinous adenocarcinomas.
Wu J et al. (2013) 12 studied 43 primary mucinous lung AC and 25 mucinous metastatic AC. They observed that overall sensitivity of NapsA (33%) in mucin-producing adenocarcinomas of the lung is lower than TTF-1 (42%) sensitivity. Compared with NapsA, TTF-1 expression is found more frequently among the majority of solid adenocarcinomas with production of mucin, colloid adenocarcinomas and signet ring cell adenocarcinomas. In tumors, previously classifi ed as mucinous bronchioloalveolar carcinomas, positivity of TTF-1 was identical to that of NapsA (11%). Invasive mucinous adenocarcinomas were associated with KRAS transition mutations. AC with extracellular mucin was associated with KRAS mutations, whereas signet-ring cell feature was not associated with EGFR or KRAS mutations. Among invasive mucinous adenocarcinomas with KRAS mutations, a pure mucinous pattern was more common than a mixed mucinous/non-mucinous pattern. 18 EGFR mutation was rarely found in solid predominant and mucinous AC. Chen Zh et al. (2014) found that the presence of well-differentiated components in lung adenocarcinoma, such as lepidic, papillary and acinar, indicates a higher EGFR mutation rate, while the solid and mucinous component indicates a lower EGFR mutation rate. 19 Based on 382 examined lung adenocarcinomas Sun PL (2012) obtained similar results as ours for the expression of EGFR -13.3% in IMA (mucinous BAC). EGFR mutations were signifi cantly more common in tumors with thyroid transcription factor-1 (TTF-1) expression than those without TTF-1, and almost all (92.7%) mutated adenocarcinomas were TTF-1 positive. TTF-1 can predict EGFR mutations. In this study, mixed (Acinar and BAC) and (Papillary and Acinar) patterns of lung adenocarcinomas with EGFR/TTF-1 protein expression are more frequently associated with EGFR mutations. 20 The results demonstrated that a lack of TTF1 expression was identifi ed more frequently in male smokers with large tumors that present advanced disease stage. TTF1 -correlated with solid and invasive mucinous subtypes of lung adenocarcinoma and lower frequency of EGFR mutations. It defi nes a subgroup of lung adenocarcinomas with unfavorable outcomes. 21 Solid patterns showed lower TTF1 and higher Ki-67 expression. TTF1 expression was higher in non-mucinous lepidic and micropapillary patterns when compared to acinar and solid and acinar, solid and mucinous respectively. Mucinous subtypes and solid patterns show lower expression of nuclear TTF1 and higher expression of Ki67, refl ecting probably a particular cell origin and more aggressive biological behaviour and have to be reported as lung adenocarcinomas, avoiding poorly differentiated carcinoma designation. 22 Our results did not indicate signifi cant differences between sensitivity and specifi city of TTF1/NapsinA in both mucinous and non-mucinous adenocarcinomas in the lung and the same mutation frequency of EGFR in mucinous AC -3/21 cases (14.3%) as mutation frequency detected in non-mucinous AC in Bulgarian region -10-15%.
CONCLUSION
We found a high proportion of primary mucinous lung AC to primary non-mucinous AC. Sensitivity and specifi city of mNapsA and TTF1 did not differ signifi cantly in pulmonary mucinous and nonmucinous AC in the RM, as mNapsA gave greater sensitivity to mucinous AC.
